Perrigo Company PLC
NYSE:PRGO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (11), the stock would be worth $18.22 (52% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 7.3 | $12.03 |
0%
|
| 3-Year Average | 11 | $18.22 |
+52%
|
| 5-Year Average | 11 | $18.28 |
+52%
|
| Industry Average | 11 | $18.26 |
+52%
|
| Country Average | 10.6 | $17.5 |
+46%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
$4.5B
|
/ |
Jan 2026
$650.3m
|
= |
|
|
$4.5B
|
/ |
Dec 2026
$627.5m
|
= |
|
|
$4.5B
|
/ |
Dec 2027
$692.2m
|
= |
|
|
$4.5B
|
/ |
Dec 2028
$732.1m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| IE |
|
Perrigo Company PLC
NYSE:PRGO
|
1.7B USD | 7.3 | -1.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
869.1B USD | 27.7 | 40.9 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.5B USD | 16.5 | 25.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.7 | 19.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
231.9B GBP | 16.2 | 29.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
226.8B CHF | 12.3 | 19.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
289.8B USD | 9.5 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 8 | 10.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.5B USD | 7.7 | 20 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119B USD | 7.1 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 6 |
| Median | 10.6 |
| 70th Percentile | 12.9 |
| Max | 338.7 |
Other Multiples
Perrigo Company PLC
Glance View
Perrigo Company PLC, a stalwart in the pharmaceutical and healthcare sectors, has carved a niche by specializing in over-the-counter (OTC) health and wellness products. This Dublin-based company traces its origins back to 1887, in Allegan, Michigan, where it began as a modest packager of home remedies. Over the decades, Perrigo has evolved into a global powerhouse that provides affordable and quality healthcare products, distributing them across various markets around the world. Its strategy hinges on delivering effective OTC solutions and a wide array of consumer self-care products, making it a familiar presence in households seeking reliable alternatives to more expensive brand-name pharmaceuticals. Perrigo's business model is centered on offering value to both consumers and retailers. By producing generic versions of well-known drugs, it captures a significant share of the market driven by cost-conscious customers. This approach also involves collaborating with retail giants to supply their private label OTC medications, a mutually beneficial arrangement that allows retailers to offer lower-cost alternatives under their own brands while maintaining healthy margins. Beyond just OTC medications, Perrigo has expanded its offerings to include nutritional products and topical solutions, further diversifying its portfolio and revenue streams. The company's consistent investment in innovation and keen attention to regulatory compliance underscore its commitment to quality and safety, attributes that resonate well in an industry guided by trust and efficacy.